Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The brokerage currently has a $28.00 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research’s price objective would suggest a potential upside of 13.36% from the stock’s previous close.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Separately, Jefferies Group reiterated a “buy” rating and set a $28.00 price objective (up previously from $23.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 4th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $25.75.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 24.70 on Friday. The stock’s 50 day moving average is $21.65 and its 200-day moving average is $21.01. Supernus Pharmaceuticals has a 12-month low of $9.51 and a 12-month high of $26.84. The stock has a market cap of $1.22 billion, a PE ratio of 50.41 and a beta of 1.86.

In other news, CFO Gregory S. Patrick sold 2,000 shares of the business’s stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the sale, the chief financial officer now owns 3,616 shares in the company, valued at approximately $90,400. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 6.10% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Cornerstone Capital Management Holdings LLC. raised its stake in Supernus Pharmaceuticals by 82.4% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 178,550 shares of the specialty pharmaceutical company’s stock valued at $4,414,000 after buying an additional 80,650 shares in the last quarter. Credit Suisse AG raised its stake in Supernus Pharmaceuticals by 1.4% in the third quarter. Credit Suisse AG now owns 91,390 shares of the specialty pharmaceutical company’s stock valued at $2,260,000 after buying an additional 1,239 shares in the last quarter. Picton Mahoney Asset Management raised its stake in Supernus Pharmaceuticals by 1.4% in the third quarter. Picton Mahoney Asset Management now owns 15,000 shares of the specialty pharmaceutical company’s stock valued at $371,000 after buying an additional 200 shares in the last quarter. 1832 Asset Management L.P. acquired a new stake in Supernus Pharmaceuticals during the third quarter valued at approximately $1,375,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Supernus Pharmaceuticals during the third quarter valued at approximately $799,000. Institutional investors and hedge funds own 97.09% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.